Notably, the authors identified the signaling lymphocytic activation molecule family member 1 (SLAMF1), a surface protein which was specifically and highly expressed in tumor ILCs (mainly ILC1-like and ILC2) and to a lower level in the blood of colon cancer patients but absent in the normal blood. Here, SLAMF1 is linked to colonic neoplasm.